U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07401303) titled 'Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time' on Feb. 03.
Brief Summary: Gastric cancer remains a major global health burden, ranking fifth in incidence worldwide and disproportionately affecting Asia, with China accounting for a significant share of cases and deaths. Early detection and minimally invasive treatment are critical to improving outcomes. Endoscopic submucosal dissection (ESD) is the preferred curative approach for early gastric cancer, enabling precise, en bloc tumor resection while preserving gastric function. However, ESD is technically complex, time-consuming, and associated with risks su...